

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-19. (Cancelled)

20. (Previously presented) A method for diagnosing colon cancer comprising detecting of differential expression of PPP3CC in a patient colon sample, wherein differential expression is detected by measuring the level of an expression product of PPP3CC; said expression product having the nucleotide sequence of SEQ ID NO:1587; wherein an increase in the level of the expression product in the sample of at least 50% relative to a non-cancerous control is indicative of colon cancer.

Claims 21-29. (Cancelled)

30. (Previously presented) The method of claim 20 wherein the non-cancerous control is a tissue of the same tissue type as in the patient sample.

31. (Cancelled)

32. (Previously presented) The method of claim 20 wherein the level of the expression product in the sample is increased at least 100% relative to the control.

33. (Previously presented) The method of claim 20 wherein the level of the expression product in the sample is increased at least 150% relative to the control.

34. (Cancelled)

35. (Previously presented) A method of diagnosing lymphoma, colon cancer, or stomach cancer comprising:

a) determining the expression level of a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1587 in a patient sample; and

b) comparing said level of the nucleic acid in (a) to a level of the nucleic acid in a second sample, said second sample comprising a non-cancerous tissue, wherein a difference between the level of the nucleic acid in (a) and the level of the expression products in the second sample indicates that the patient has lymphoma, colon cancer, or stomach cancer.

Claims 36-42 (Cancelled)

43. (Previously presented) A method for diagnosing colon cancer comprising comparing levels of PPP3CC protein in a patient colon sample to that of a non-cancerous colon control sample, wherein the PPP3CC protein is encoded by a nucleic acid having the nucleotide sequence set forth in SEQ ID NO:1587, wherein an increase in the level of PPP3CC protein in the patient colon sample of at least 50% relative to said non-cancerous colon control is indicative of colon cancer.

44. (Previously presented) A method for diagnosing colon cancer comprising comparing levels of a polypeptide encoded for by a nucleic acid comprising a nucleotide sequence at least 98% identical to SEQ ID NO:1587 in a patient colon sample to a non-cancerous colon control sample, wherein an increase in the level of the polypeptide in the patient colon sample of at least 50% relative to said non-cancerous colon control is indicative of colon cancer, said polypeptide having protein phosphatase activity.

Claims 45-48. (Cancelled)